Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Engineered ICOSL Peptide Therapy Targets Integrin to Reduce Glomerular Kidney Damage

1 hour ago 4

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Biomedical researchers have engineered a targeted peptide derived from inducible co-stimulator ligand that binds and selectively inhibits activated alpha-v-beta-3 integrin on glomerular podocytes, significantly attenuating proteinuria and preserving renal architecture across multiple preclinical models of acute and chronic kidney injury. In proteinuric kidney diseases, structural disruption of the glomerular filtration barrier arises when podocytes lose their delicate foot process morphology and detach from the underlying basement membrane. Despite the established pathological contribution of aberrantly activated alpha-v-beta-3 integrin to these filtration defects, clinical medicine currently possesses no approved therapeutic agents that directly inhibit this cell-surface receptor in renal tissue. By isolating the endogenous integrin-binding motif of inducible co-stimulator ligand from its traditional immune-modulatory domains, investigators established an innovative molecular approach to halt podocyte injury and reduce renal damage without provoking unwanted immune activation or cellular toxicity.

Integrin receptors serve indispensable structural functions within the kidney by anchoring podocyte foot processes to the glomerular basement membrane and stabilizing the filtration slit architecture responsible for selective blood ultrafiltration. Under healthy physiological conditions, these heterodimeric adhesion molecules modulate cytoskeletal organization and maintain filtration integrity, but abnormal integrin expression or pathological activation rapidly destabilizes the filtration slit apparatus. Dysregulated activation of alpha-v-beta-3 integrin represents a recognized hallmark of renal inflammation and acts as a central driver of pathological proteinuria in glomerular disorders, most prominently focal segmental glomerulosclerosis and diabetic nephropathy. Pathological stimulation of alpha-v-beta-3 integrin can be triggered by canonical extracellular matrix ligands containing arginine-glycine-aspartic acid sequences, including vitronectin, fibronectin, and osteopontin, as well as distinct non-canonical circulating factors linked to progressive kidney disease, such as triiodothyronine, angiopoietin-like 3, advanced glycation end-products, and soluble urokinase plasminogen activator receptor.

Although blocking alpha-v-beta-3 integrin has long represented an attractive strategy to preserve kidney function, translating integrin inhibitors into viable clinical treatments has faced formidable pharmacological obstacles across multiple drug classes. Monoclonal antibodies directed against integrins carry substantial risks of inducing immunogenic neutralizing responses during long-term administration, while synthetic small-molecule inhibitors frequently suffer from off-target binding and inadequate receptor selectivity. Furthermore, previously developed peptidomimetic antagonists, such as the cyclic pentapeptide cilengitide, exhibited paradoxical dose-dependent effects, shifting from receptor antagonism at higher concentrations to undesirable integrin agonism at lower concentrations during clinical trials. These paradoxical signaling effects and pharmacological liabilities led to trial failures in oncology and stalled clinical translation in nephrology, underscoring the critical necessity for alternative molecular designs capable of cleanly restraining pathological integrin activation without inducing paradoxical receptor activation or systemic immunogenicity.

To overcome these historical limitations, the research team focused on inducible co-stimulator ligand, a cell-surface molecule historically characterized as an immune co-stimulatory factor that engages the ICOS receptor to stimulate T cells. Although inducible co-stimulator ligand expression increases within kidney tissue during crescentic glomerulonephritis and endotoxin-induced acute kidney injury, earlier experimental findings revealed that genetic deletion or pharmacological blockade of this protein paradoxically worsened functional renal impairment. Subsequent biochemical investigations demonstrated that inducible co-stimulator ligand exerts a vital, noncanonical renoprotective function entirely independent of its immunological role in T-cell activation. Specifically, the intact molecule contains an arginine-glycine-aspartic acid motif through which it binds with high preference to the active conformation of alpha-v-beta-3 integrin, functioning as a native competitive antagonist that limits deleterious integrin signaling in renal cells.

Leveraging this natural defense mechanism, the investigators employed structural modeling to design a compact 19-amino-acid peptide designated hICOSL-19, derived from the IgV domain of human inducible co-stimulator ligand spanning residues R83 through F101. Guided by published crystal structures, the team engineered this 2.3-kilodalton peptide to preserve the essential arginine-glycine-aspartic acid sequence along with adjacent alpha-helical and beta-sheet structural elements required for integrin recognition. Crucially, the peptide sequence was chosen from a region spatially segregated from the membrane-distal ICOS-binding interface, completely excluding the key contact residues along the GFCC-prime face, including Y51, Y53, Q55, L114, L116, and F122. By physically dissociating the integrin-binding sequence from the receptor-binding surface that governs immune co-stimulation, the researchers produced a candidate therapeutic capable of engaging alpha-v-beta-3 integrin while remaining immunologically silent with respect to canonical T-cell signaling pathways.

Rigorous biophysical characterization confirmed that the synthetic peptide inherited the binding fidelity and high affinity of the parental full-length protein. Surface plasmon resonance assays conducted under manganese-activated conditions revealed that full-length human inducible co-stimulator ligand bound human alpha-v-beta-3 integrin with an equilibrium dissociation constant of 18.6 nanomolar, exhibiting markedly weaker affinities for other integrin family members including alpha-v-beta-1, alpha-v-beta-6, alpha-v-beta-8, and alpha-5-beta-1, while showing no detectable interaction with alpha-IIb-beta-3 or alpha-v-beta-5. Correspondingly, the engineered hICOSL-19 peptide exhibited high-affinity binding to human alpha-v-beta-3 integrin with a dissociation constant of 25.4 nanomolar and bound mouse alpha-v-beta-3 at 44.9 nanomolar, whereas a scrambled control peptide showed no measurable interaction. Competitive binding assays with cilengitide confirmed that binding was strictly dependent on the arginine-glycine-aspartic acid motif, while in situ proximity ligation assays verified close physical proximity between the ligand and alpha-v-beta-3 integrin in cultured human podocytes and human diabetic kidney biopsies.

In cultured human and mouse podocytes, hICOSL-19 promoted cell adhesion under manganese stimulation at levels comparable to vitronectin and full-length inducible co-stimulator ligand, an interaction that was abolished by pre-incubation with integrin-blocking antibodies or competitive peptide blockers. When applied competitively, hICOSL-19 effectively displaced vitronectin from podocyte integrins and suppressed downstream focal adhesion kinase phosphorylation at tyrosine-397, a critical intracellular signaling event driving cytoskeletal rearrangement and foot process effacement. Because unmodified peptides typically undergo rapid systemic degradation, pharmacokinetic analysis of fluorescein-labeled hICOSL-19 revealed a terminal plasma elimination half-life of 14.96 minutes in vivo. To overcome this limitation, the peptide was conjugated at its amino terminus with twelve polyethylene glycol units, yielding PhICOSL-19 with a molecular mass of approximately 2.73 kilodaltons. This modification extended the terminal elimination half-life more than three-fold to 46.74 minutes while fully preserving target affinity, anti-adhesive activity, and the capacity to block focal adhesion kinase phosphorylation.

The therapeutic efficacy of once-daily systemic PhICOSL-19 administration was subsequently evaluated in complementary rodent models reproducing acute, chronic, and autoimmune glomerulopathy. In an acute passive anti-glomerular basement membrane nephritis model established in mice lacking endogenous inducible co-stimulator ligand, intravenous administration of PhICOSL-19 produced statistically significant reductions in urinary protein excretion after 24 and 48 hours relative to saline-treated animals. In an active, chronic nephrotoxic serum glomerulonephritis model induced in pre-immunized BALB/c mice exhibiting severe baseline proteinuria, a five-day therapeutic regimen of PhICOSL-19 at 500 micrograms per kilogram daily significantly lowered the urinary albumin-to-creatinine ratio compared to treatment with a PEGylated control peptide containing an inactive alanine-alanine-alanine substitution. Histopathological scoring of periodic acid-Schiff stained renal tissue revealed markedly attenuated glomerular hypercellularity and crescent formation, while transmission electron microscopy demonstrated substantial restoration of podocyte foot processes along the capillary loops.

The investigative team extended their therapeutic evaluation to progressive metabolic renal disease using five-week-old BTBR ob/ob mice, an established genetic model of severe obesity and advanced diabetic nephropathy characterized by marked baseline albuminuria. Daily intravenous administration of PhICOSL-19 at 500 micrograms per kilogram for six consecutive weeks led to significant decreases in both the urinary albumin-to-creatinine ratio and 24-hour total urinary albumin excretion when contrasted with animals receiving the control mutant peptide. Importantly, these substantial functional improvements were achieved without altering overall animal body weight over the six-week treatment course. Quantitative histological and ultrastructural evaluations corroborated these functional renal improvements, revealing significant reductions in glomerular injury scores, diminished podocyte foot process effacement, and the structural normalization of glomerular basement membrane thickening, which represents a classical morphological hallmark of diabetic renal microvascular disease.

Parallel safety and immunogenicity studies confirmed that the therapeutic peptide exhibited an exceptionally clean biological profile in both cell culture assays and animal models. Exposure of differentiated human podocytes to escalating concentrations of PhICOSL-19 over 96 hours induced no detectable changes in filamentous actin cytoskeletal organization, cell numbers, surface areas, cellular ATP concentrations, or metabolic dehydrogenase activities, and produced no release of extracellular lactate dehydrogenase. In vitro stimulation of human Jurkat T cells and peripheral blood mononuclear cells demonstrated no induction of the early activation marker CD69, confirming the complete absence of classical immune co-stimulation. Furthermore, healthy mice treated daily with intravenous PhICOSL-19 for four weeks exhibited normal weight gain, normal splenic morphology, and baseline levels of CD69-positive splenic T cells, while indirect enzyme-linked immunosorbent assays showed no statistically significant induction of circulating anti-drug antibodies compared to untreated animals.

While these preclinical findings provide robust proof of concept for converting an endogenous renoprotective mechanism into an engineered peptide therapeutic, the authors highlighted important experimental boundaries and translational questions warranting further investigation. The efficacy trials evaluated a single intravenous dosage of 500 micrograms per kilogram, leaving dose-response relationships, alternative administration routes, and pharmacokinetic optimization to be established in future work. Furthermore, the diabetic cohort utilized a modest sample size that must be confirmed across larger animal cohorts and extended disease timeframes. Because modern clinical nephrology relies heavily on combination regimens, future studies must examine how targeted integrin inhibition interacts with established standards of care, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists. Nonetheless, by demonstrating durable podocyte protection across distinct mechanical, metabolic, and immunological injury models, this engineered peptide strategy establishes a promising therapeutic paradigm for directly targeting alpha-v-beta-3 integrin in proteinuric kidney disorders.

Subject of Research: Preclinical evaluation of an ICOSL-derived peptide targeting alpha-v-beta-3 integrin in proteinuric kidney diseases

Article Title: An inducible co-stimulator ligand (ICOSL)-based peptide therapy for proteinuric kidney diseases targeting αvβ3 integrin

Article References: Jimenez-Uribe, A. P., Xu, Y., Cao, Y., Spear, R., Koh, K. H., Mansini, A. P., Alcantar, A. G., Kliewe, F., Endlich, N., Reiser, J., Mangos, S., & Hahm, E. (2026). An inducible co-stimulator ligand (ICOSL)-based peptide therapy for proteinuric kidney diseases targeting αvβ3 integrin. Molecular Biomedicine, 7(1), Article 200. https://doi.org/10.1186/s43556-026-00594-2

Image Credits: AI Generated

DOI: 10.1186/s43556-026-00594-2

Keywords: ICOSL, alpha-v-beta-3 integrin, podocytes, proteinuria, diabetic nephropathy, glomerulonephritis, peptide therapeutics, PEGylation, kidney disease, glomerular filtration barrier, foot process effacement, focal adhesion kinase, nephrotoxic serum nephritis, BTBR ob/ob mice, suPAR, targeted therapy

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway